1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. BioDelivery Acquires Arcion Therapeutics - Topical Clonidine Gel

M&A Deal Summary

BioDelivery Acquires Arcion Therapeutics - Topical Clonidine Gel

On March 26, 2013, BioDelivery acquired life science company Arcion Therapeutics - Topical Clonidine Gel from Arcion Therapeutics

Acquisition Highlights
  • This is BioDelivery’s 1st transaction in the Life Science sector.
  • This is BioDelivery’s 1st transaction in the United States.

M&A Deal Summary
Date 2013-03-26
Target Arcion Therapeutics - Topical Clonidine Gel
Sector Life Science
Buyer(s) BioDelivery
Sellers(s) Arcion Therapeutics
Deal Type Divestiture

Target

Arcion Therapeutics - Topical Clonidine Gel

United States
Arcion Therapeutics - Topical Clonidine Gel is used for the treatment of painful diabetic neuropathy (PDN) and potentially other indications. The PDN market is highly under-served by existing products and there is a strong scientific rationale for developing a topical treatment for PDN that delivers analgesia in a way that avoids systemic side effects.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

BioDelivery

Raleigh, North Carolina, United States
Category Company
Founded 1997
Sector Life Science
Employees176
Revenue 156M USD (2020)
DESCRIPTION

BioDelivery is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BioDelivery was formed in 1997 and is based in Raleigh, North Carolina.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2013 M&A 1 of 1

Seller(S) 1

SELLER

Arcion Therapeutics

Baltimore, Maryland, United States
Category Company
Sector Life Science
DESCRIPTION

Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain; ARC-4558 (topical clonidine gel) for PDN and ARC-2022 (high potency lidocaine gel) for PHN.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2013 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal